The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients
Open accessAbstract
Sirolimus (Rapammune, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection. Hyperlipidemia is a significant side effect of sirolimus treatment, and frequently leads to cardiovascular disease. This study was undertaken to determine the repeatability, reversibility, and dose dependence of the plasma lipid and apolipoprotein altering effects of sirolimus, and to elucidate the mechanism by which sirolimus induces hypertriglyceridemia in some renal transplant patients. Six patients with renal allografts maintained on cyclosporine A and prednisone were selected on the basis of their previous hyperlipidemic response to short term (14 days) sirolimus administration. For longer-term treatment, each patient was started on 10 mg/day sirolimus and continued as tolerated for 42 days to reinduce hyperlipidemia. Timed blood samples were analyzed for lipid, apolipoprotein, and sirolimus levels. During sirolimus administration, mean total plasma cholesterol increased from 214 mg/dl to 322 mg/dl (+50%; range 25-92%); LDL-cholesterol levels followed a similar pattern. Mean triglyceride level rose from 227 to 432 mg/dl (+95%; range 9-254%). ApoB-100 concentration rose from 124 to 160 mg/dl (+28%; P < 0.05). ApoC-III level increased from 28.9 to 55.5 mg/dl, +92%; (P < 0.013). These lipid and apolipoprotein changes were found to be repeatable, reversible, and dose dependent. [(13)C(4)]palmitate metabolic studies in four patients with hypertriglyceridemia indicated that the free fatty acid pool was expanded by sirolimus treatment (mean = 42.3%). Incorporation of [(13)C(4)]palmitate into triglycerides of VLDL, IDL, and LDL was decreased 38.3%, 42,1%, and 38.4%, respectively, by sirolimus treatment of these patients. These results suggest that sirolimus alters the insulin signaling pathway so as to increase adipose tissue lipase activity and/or decrease lipoprotein lipase activity, resulting in increased hepatic synthesis of triglyceride, increased secretion of VLDL, and increased hypertriglyceridemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 2 Percent atom enrichment in the free fatty acid fractions of plasma collected during/after infusion of [ 13 C 4]palmitate into four renal transplant patients before (odd number, solid lines) and after 6 weeks of (even number, dashed lines) sirolimus treatment. The integrated area under each curve is tabulated in Table 6.](https://figures.cochat.ai/paper-figures/cf82f4a6fbe64527986a83789bd442b9/effects-of-sirolimus-on-plasma-lipids-lipoprotein-levels-and-fatty-acid-figure-2.png)
![Fig. 3 Incorporation of [ 13 C 4]palmitate into triglycerides of VLDL, IDL, and LDL of patient WAS-7/8 before (solid lines) and after 6 weeks of (dashed lines) sirolimus treatment.](https://figures.cochat.ai/paper-figures/f2c1e8a84517456b8ea35a4aced67518/effects-of-sirolimus-on-plasma-lipids-lipoprotein-levels-and-fatty-acid-figure-3.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, this has not been confirmed in RCTs [266,479-481], or in meta-analyses of observational and randomized trials [482,483].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [483]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Warnick, G. R., Benderson, J., & Albers, J. J. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.6.1379 · Cited by 2,159
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 1×
“mTOR controls proteins that regulate mRNA translation initiation and G1 progression ( 7 ).”
BackgroundRAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,138
Separation of plasma lipoproteins by density-gradient ultracentrifugation
Redgrave, T. G., Roberts, D. C. K., & West, C. E. (1975) · Analytical Biochemistry · doi:10.1016/0003-2697(75)90488-1 · Cited by 1,107 · cited 1×
“Blood samples (15 ml) were drawn, 18 over the first 24 h and 1 daily for the next 5 days, from which VLDL, IDL, and LDL were isolated by density gradient ultracentrifugation ( 21 ).”
MethodSiedel, J., Hägele, E. O., Ziegenhorn, J., & Wahlefeld, A. W. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.6.1075 · Cited by 942
Kahan, B. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02480-6 · Cited by 913
Self-citationPhosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin
Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 846
MacDonald, A. S. (2001) · Transplantation · doi:10.1097/00007890-200101270-00019 · Cited by 621
[54] Thin-layer chromatography of lipids
(1969) · Methods in Enzymology · doi:10.1016/s0076-6879(69)14056-2 · Cited by 573
Research works printed but not linked: 2
- Mac Donald, 2001, The Rapamune Global Study Group: a randomized, placebo-controlled trial of rapammune in primary renal allograft recipients, Transplantation., 71, 271
- Morrisett, 2001, Effect of rapamycin on free fatty acid metabolism in renal transplant patients, Arterioscler. Thromb. Vasc. Biol., 21, 654
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
mTORC1 signaling and the metabolic control of cell growth
Ben-Sahra, I., & Manning, B. D. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.02.012 · Cited by 644
“An increase in circulating lipids is a feature of systemic rapamycin treatment in humans [96,97], and this is also observed in mice with loss of function mutations in the mTOR pathway [98].”
Background
Metadata
- Authors
- Morrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D.
- Affiliations
- Baylor College of Medicine (US)
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Morrisett, Joel D.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 43
- Issue
- 8
- Pages
- 1170-1180
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W1783019770
- Cited by
- 295
- References
- 38
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 9 · 2023: 10 · 2022: 15 · 2021: 10 · 2020: 12 · 2019: 6 · 2018: 12 · 2017: 16 · 2016: 20 · 2015: 14 · 2014: 23 · 2013: 14 · 2012: 22
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6609 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Public Health Service (DL 38016)
- National Heart, Lung, and Blood Institute (HL-07812, T32HL007812)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- rapamycin, kidney transplantation, hyperlipidemia, hypertriglyceridemia, plasma lipids, apolipoproteins, apolipoprotein B-100, apolipoprotein C-III, fatty acid metabolism, palmitate incorporation, lipoprotein lipase, adipose tissue lipase, insulin signaling, cyclosporine
- MeSH terms
- Adult, Cholesterol, Fatty Acids, Nonesterified, Female, Humans, Immunosuppressive Agents, Lipoproteins, Male, Middle Aged, Triglycerides, Kidney Transplantation, Sirolimus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. https://app.cochat.ai/papers/10.1194/jlr.m100392-jlr200
- The paper
- Morrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D. (2002). Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. Journal of Lipid Research. https://doi.org/10.1194/jlr.m100392-jlr200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.